The FDA recently approved Inrebic® (Fedretinib) for Myelofibrosis, the first new treatment in decades. Available as a once-daily oral dose, this is a new option for patients. Learn more: https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx